Comparative Pharmacology
Head-to-head clinical analysis: ELIXOPHYLLIN SR versus QUIBRON T.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXOPHYLLIN SR versus QUIBRON T.
ELIXOPHYLLIN SR vs QUIBRON-T
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.
Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular cAMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.
300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in adults (nonsmokers). In smokers, hepatic clearance is increased, reducing half-life to 4-5 hours. In patients with hepatic cirrhosis, half-life may extend to 24 hours. In neonates, half-life is prolonged (20-30 hours).
Terminal elimination half-life: 7-9 hours in nonsmoking adults; prolonged in hepatic cirrhosis (up to 30 hours) or heart failure; shorter in smokers (4-5 hours) due to enzyme induction.
Renal: approximately 90% of the dose is eliminated via hepatic metabolism (N-demethylation and hydroxylation), with about 10% excreted unchanged in urine. The primary metabolites are 1-methylxanthine, 1,3-dimethyluric acid, and 3-methylxanthine. Fecal excretion is negligible (<1%).
Renal: 70% as metabolites (1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid) and 10% as unchanged drug in adults; biliary/fecal: minimal, <5%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator